Bladder Adjuvant Radiotherapy: Phase III Multicenter Randomized Controlled Trial of Adjuvant Radiotherapy or Observation for Postcystectomy Muscle-Invasive Bladder Cancer - PubMed
4 hours ago
- #radical cystectomy
- #muscle-invasive bladder cancer
- #adjuvant radiotherapy
- A phase III randomized trial assessed adjuvant radiotherapy (RT) versus observation in high-risk muscle-invasive bladder cancer (MIBC) post-cystectomy and chemotherapy.
- The 2-year locoregional recurrence-free survival (LRFS) was significantly higher with adjuvant RT (87.1%) compared to observation (76.0%), with a hazard ratio (HR) of 0.43.
- Adjuvant RT also showed potential benefits in disease-free survival (DFS), bladder cancer-specific survival (BCSS), and overall survival (OS), though these results were not statistically significant.
- The study used stoma-sparing IG-IMRT at 50.4 Gy over 28 fractions and involved patients with high-risk features like T3-4, N1-3, positive margins, or ≤10 lymph nodes dissected.
- No additional severe toxicity was reported, suggesting adjuvant RT may improve locoregional control in high-risk MIBC patients without significant harm.